Hanmi Pharm (128940) Stock Price, Fundamentals & Analysis

What 128940 does

Hanmi Pharm (128940) is a biopharmaceutical company that manufactures and sells pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. One of its products is Gugutams, a urological combination therapy that combines tamsulosin for Obstructive Prostatic Growth (OPG) and tadalafil for erectile dysfunction (ED). The company also has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. Hanmi Pharm is listed on the Korea Exchange and operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

Key numbers explained

• 520,000 KRW is the current share price, representing the last traded price on the exchange.
• +3.59% is the price change today, showing the percentage move from the previous close.
• 6.6T KRW is the market capitalization, the total market value of all outstanding shares.
• The forward P/E ratio of 29.8 divides the current price by expected future earnings, helping investors gauge how much they pay per unit of anticipated profit.
• The dividend yield of 0.38% shows the annual dividend as a percentage of the share price, indicating the cash return relative to the price paid.
• 12% is the share of earnings paid out as dividends, meaning the company distributes a small portion of its profit to shareholders.
• 0.56 is the beta, a measure of the stock's volatility relative to the overall market; a value below 1 suggests lower sensitivity to market swings.
• The 52-week range of 302,000 – 647,000 shows the lowest and highest prices over the past year, providing context for the current price level.

What to watch

Investors tracking Hanmi Pharm (128940) may monitor its revenue growth, which has been 29.3% year over year, and its profit margin of 13.1%, which reflects how much of each sales dollar becomes profit. The company's research pipeline in obesity, metabolism, oncology, and rare diseases can influence long-term expectations. As a Healthcare stock, it may be sensitive to regulatory approvals, drug pricing policies, and clinical trial results. Its relatively low beta of 0.56 suggests it may experience smaller price swings than the broader market, which can appeal to risk-conscious investors. For those interested in peer companies, SK Biopharm (326030), Hanall Biopharma (009420), and Celltrion (068270) operate in related segments of the Korean healthcare space.